The effectiveness is a procedural step with no direct financial impact on Vor Biopharma. Monitor for any subsequent prospectus supplements that could indicate accelerated selling by TCG Crossover Funds, which may create near-term overhang. The prior effective shelf from January 2026 covering 13.9M shares remains an additional overhang factor.
VOR drugs
VOR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $16.08entry
- T+1 · 6mo ago +5.35%α +4.52% · $16.94
- T+5 · 6mo ago −1.06%α −2.56% · $15.91
- T+20 · 6mo ago −16.42%α −19.55% · $13.44
- T+60 · 4mo ago +33.15%α +29.31% · $21.41
Price Chart
How similar events traded
Executive Summary
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of up to 5,338,078 shares of common stock held by TCG Crossover Funds from a March 2026 private placement. The company will not receive any proceeds from these sales. This is a routine registration rights fulfillment and does not represent new equity issuance or a capital raise for the company.
Key Facts
- S-3 registration (File No. 333-295346) declared effective on May 6, 2026.
- Registration covers 5,338,078 shares of common stock for resale by TCG Crossover Funds.
- Shares were issued in a March 2026 private placement at $14.05 per share ($75M gross).
- Vor Biopharma will not receive any proceeds from the resale.
- This is a routine registration rights fulfillment, not a new capital raise.
- The company has a prior S-3 effective from January 2026 covering 13,876,032 shares from a December 2025 private placement.
Financial Impact
No financial impact on Vor Biopharma; the company receives no proceeds from the resale.
Risk Factors
- Potential near-term selling pressure if TCG Crossover Funds execute resales aggressively.
- Combined overhang from two effective shelves (5.3M + 13.9M shares) could weigh on stock price.
- No new capital raised for the company, limiting upside catalyst from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001527 |
| Document: 9999999995-26-001527-index.html | 9999999995-26-001527 |
| Document: 9999999995-26-001527.txt | 9999999995-26-001527 |
Track record
17 reports on VOR
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
- Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
- Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
- Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers